IR@PKUHSC  > 北京大学精神卫生研究所
学科主题精神卫生
A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia
Zhang, XY1; Zhou, DF1; Zhang, PY1; Wu, GY1; Su, JM1; Cao, LY1
刊名JOURNAL OF CLINICAL PSYCHIATRY
2001-11-01
62期:11页:878-883
收录类别SCI ; SSCI
文章类型Article
WOS标题词Social Sciences ; Science & Technology
类目[WOS]Psychology, Clinical ; Psychiatry
研究领域[WOS]Psychology ; Psychiatry
关键词[WOS]FREE-RADICAL PATHOLOGY ; ANTIOXIDANT DEFENSE ; ASCORBIC-ACID
英文摘要

Background: Many studies have indicated that excess free radical formation may be involved in the pathogenesis of patients with schizophrenia. Some investigators suggested that the use of free radical scavengers might provide improvement in schizophrenia. The aim of this study was to determine the effectiveness and to evaluate the side effects of extract of Ginkgo biloba (EGb) plus haloperidol in chronic, treatment-resistant inpatients with schizophrenia.

Method: One hundred nine patients meeting DSM-III-R criteria for schizophrenia completed a double-blind, placebo-controlled, parallel-group study of EGb plus haloperidol. Fifty-six of the patients were randomly assigned to receive a fixed dose of 360 mg/day of EGb plus a stable dose of haloperidol, 0.25 mg/kg/day, and 53 were assigned to receive placebo plus the same dose of haloperidol for 12 weeks. Patients were assessed using the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Negative Symptoms (SANS), and the Scale for the Assessment of Positive Symptoms (SAPS) at baseline, week 6, and week 12 and the Treatment Emergent Symptom Scale (TESS) for side effects at week 12.

Results: There was a significant reduction in both groups in BPRS total score after 12 weeks of treatment (p < .05). However, a significant reduction in total SAPS and SANS scores was noted in the EGb group (p < .05), but not in the placebo group. There was a lower SAPS total score in the EGb group than in the placebo group at the end of 12 weeks of treatment (p < .05). Of those treated with EGb plus haloperidol, 57.1% were rated as responders as compared with only 37.7% of those receiving placebo plus haloperidol when assessed by the SAPS (chi (2) = 4.111, p = .043). After 12 weeks of treatment, TESS subscore 1 (behavioral toxicity) and subscore 3 (symptoms of nerve system) were significantly decreased in the EGb group compared with the placebo group (p < .05).

Conclusion: EGb treatment may enhance the effectiveness of antipsychotic drugs and reduce their extrapyramidal side effects.

语种英语
WOS记录号WOS:000172680500007
引用统计
被引频次:67[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52347
专题北京大学精神卫生研究所
作者单位1.Beijing Huilongguan Hosp, Beijing, Peoples R China
2.Yale Univ, Sch Med, Neuropsychopharmacol Lab, New Haven, CT 06520 USA
3.Beijing Med Univ, Inst Mental Hlth, Beijing 100083, Peoples R China
推荐引用方式
GB/T 7714
Zhang, XY,Zhou, DF,Zhang, PY,et al. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia[J]. JOURNAL OF CLINICAL PSYCHIATRY,2001,62(11):878-883.
APA Zhang, XY,Zhou, DF,Zhang, PY,Wu, GY,Su, JM,&Cao, LY.(2001).A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia.JOURNAL OF CLINICAL PSYCHIATRY,62(11),878-883.
MLA Zhang, XY,et al."A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia".JOURNAL OF CLINICAL PSYCHIATRY 62.11(2001):878-883.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhang, XY]的文章
[Zhou, DF]的文章
[Zhang, PY]的文章
百度学术
百度学术中相似的文章
[Zhang, XY]的文章
[Zhou, DF]的文章
[Zhang, PY]的文章
必应学术
必应学术中相似的文章
[Zhang, XY]的文章
[Zhou, DF]的文章
[Zhang, PY]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。